Crystalline form of 1-choloro-4-(beta-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments

Abstract

The invention relates to a crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.

1 . (canceled) 
   
   
       2 . (canceled) 
   
   
       3 . (canceled) 
   
   
       4 . (canceled) 
   
   
       5 . (canceled) 
   
   
       6 . A method of treating or preventing diseases or conditions that can be influenced by inhibiting the sodium dependent glucose cotransporter SGLT in a patient in need thereof, said method comprised of the steps of administering to a patient in need thereof a therapeutically effective amount of a crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene having an X-ray powder diffraction pattern that comprises peaks at 18.84, 20.36 and 25.21 degrees 2 ⊖±0.05 degrees 2  , wherein said X-ray powder diffraction pattern is made using CuK α1  radiation. 
   
   
       7 . A method of treating or preventing metabolic disorders, in particular a metabolic disorder selected from the group consisting of type 1 and type 2 diabetes mellitus, complications of diabetes, metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, obesity, high blood pressure, chronic heart failure, oedema and hyperuricaemia said method comprised of the steps of administering to a patient in need thereof a therapeutically effective amount of a crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene having an X-ray powder diffraction pattern that comprises peaks at 18.84, 20.36 and 25.21 degrees 2⊖±0.05 degrees 2  , wherein said X-ray powder diffraction pattern is made using CuK α1  radiation. 
   
   
       8 . A method of inhibiting the sodium-dependent glucose cotransporter SGLT2, said method comprised of the steps of administering to a patient in need thereof a therapeutically effective amount of a crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene having an X-ray powder diffraction pattern that comprises peaks at 18.84, 20.36 and 25.21 degrees 2 ⊖±0.05 degrees 2  , wherein said X-ray powder diffraction pattern is made using CuK α1  radiation. 
   
   
       9 . A method of treating or preventing degeneration of pancreatic beta cells and/or for improving and/or restoring the functionality of pancreatic beta cells said method comprised of the steps of administering to a patient in need thereof a therapeutically effective amount of a crystalline form of 1-chloro-4-(β-D-glucoranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzl]-benzene having an X-ray powder diffraction pattern that comprises peaks at 18.84, 20.36 and 25.21 degrees 2⊖±0.05 degrees 2  , wherein said X-ray powder diffraction pattern is made using CuK α1  radiation. 
   
   
       10 . (canceled) 
   
   
       11 . The method according to  claim 6 , wherein the X-ray powder diffraction pattern further comprises peaks at 14.69, 19.16 and 19.50 degrees 2 ⊖±0.05 degrees 2  , wherein said X-ray powder diffraction pattern is made using CuK α1  radiation. 
   
   
       12 . The method according to  claim 7 , wherein the X-ray powder diffraction pattern further comprises peaks at 14.69, 19.16 and 19.50 degrees 2 ⊖±0.05 degrees 2  , wherein said X-ray powder diffraction pattern is made using CuK α1  radiation. 
   
   
       13 . The method according to  claim 8 , wherein the X-ray powder diffraction pattern further comprises peaks at 14.69, 19.16 and 19.50 degrees 2 ⊖±0.05 degrees 2  , wherein said X-ray powder diffraction pattern is made using CuK α1  radiation. 
   
   
       14 . The method according to  claim 9 , wherein the X-ray powder diffraction pattern further comprises peaks at 14.69, 19.16 and 19.50 degrees 2 ⊖±0.05 degrees 2  , wherein said X-ray powder diffraction pattern is made using CuK α1  radiation.